Search Results - "Van Zyl, Ruaan"

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial by Oliveira, Mafalda, Pominchuk, Denys, Nowecki, Zbigniew, Hamilton, Erika, Kulyaba, Yaroslav, Andabekov, Timur, Hotko, Yevhen, Melkadze, Tamar, Nemsadze, Gia, Neven, Patrick, Vladimirov, Vladimir, Zamagni, Claudio, Denys, Hannelore, Forget, Frédéric, Horvath, Zsolt, Nesterova, Alfiya, Ajimi, Maxine, Kirova, Bistra, Klinowska, Teresa, Lindemann, Justin P O, Lissa, Delphine, Mathewson, Alastair, Morrow, Christopher J, Traugottova, Zuzana, van Zyl, Ruaan, Arkania, Ekaterine

“…Resistance to endocrine therapies in hormone receptor-positive breast cancer is challenging. We aimed to assess the next-generation oral selective oestrogen…”
Get full text

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial by Oliveira, Mafalda, Pominchuck, Denys, Nowecki, Zbigniew, Hamilton, Erika, Kulyaba, Yaroslav, Andabekov, Timur, Hotko, Yevhen, Melkadze, Tamar, Nemsadze, Gia, Neven, Patrick, Semegen, Yuriy, Vladmirov, Vladmir, Zamagni, Claudio, Denys, Hannelore, Forget, Frederic, Horvath, Zsolt, Nesterova, Alfiya, Bennett, Maxine, Kirova, Bistra, Klinowska, Teresa, Lindemann, Justin, Lissa, Delphine, Mathewson, Alastair, Morrow, Christopher, Traugottova, Zuzana, Van Zyl, Ruaan, Arkania, Ekaterine

“…Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in…”
Get full text